As the cellular therapy industry continues to advance at a rapid pace, our organization is continually looking for ways to make a big impact on more patients’ lives, and ultimately, fulfill our mission of saving lives through cellular therapy.
Within the past year, we’ve made investments in two early stage biotechnology companies, in an effort to support innovation that will accelerate advances in the science and discovery of cell therapies.
Our first investment in May 2017 was in Magenta Therapeutics. We were excited to invest in Magenta, because we see it as a company that can unlock the potential of bone marrow transplantation across multiple diseases. This was also a big opportunity for us to explore additional ways that Be The Match BioTherapies could partner with Magenta across their discovery, clinical development and product delivery efforts.
Most recently, the opportunity arose to participate in the Series A financing round for Tmunity Therapeutics. According to Amy Ronneberg, president of Be The Match BioTherapies, “We are excited to support the mission of Tmunity Therapeutics, an early stage company that is working to build on the inspiring momentum of the field in creating personalized next-generation immunotherapies for cancer and other diseases.”
Our investments in promising early stage biotechnology companies are just one part of our overall strategy to support innovation that will accelerate advances in cell therapy. We aim to forge strong relationships with a range of industry leaders, and we hope that by applying our expertise, insights and capital, we can help drive growth in the field, which will influence the lives of patients for years to come.